Position in NVS
as of Jun 30, 2026
· filed Aug 5, 2026
Position Value
$222,699
New position
Shares Held
1,421
first reported quarter
Ownership
0.000%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
#1,270
of 1,603 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 83%
Shared 17%
None 0%
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Gryphon Financial Partners LLC holds $43,846,091 across 10 Drug Manufacturers - General names. NVS ranks #9 (0.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ABBV |
AbbVie Inc.
|
91,741 | $23,085,705 | |
| 2 | LLY |
ELI LILLY & Co
|
6,418 | $7,697,942 | |
| 3 | JNJ |
Johnson & Johnson
|
25,825 | $6,558,775 | |
| 4 | AMGN |
Amgen Inc
|
5,868 | $2,124,920 | |
| 5 | MRK |
Merck & Co., Inc.
|
16,044 | $2,061,654 | |
| 6 | GILD |
Gilead Sciences, Inc.
|
6,540 | $826,263 | |
| 7 | GSK |
GSK plc
|
15,580 | $816,703 | |
| 8 | BMY |
Bristol Myers Squibb Co
|
4,157 | $239,526 |
All Filings in NVS
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $222,699 | 1,421 | Shares | Sole | 2026-08-05 | |
| No filing history on record for this holder in this stock. | ||||||